Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19944215 | 1.00 | GSK3A (0.36) | GSK3AGSK3BADORA1ADORA3KDM4E | |
| SCHEMBL21117478 | 1.00 | GSK3A (0.36) | GSK3AGSK3BADORA1ADORA3KDM4E | |
| SCHEMBL19944682 | 1.00 | GSK3A (0.36) | GSK3AGSK3BADORA1ADORA3KDM4E | |
| SCHEMBL19944648 | 0.89 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL21117644 | 0.89 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL19944645 | 0.89 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL19944647 | 0.89 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL21117659 | 0.88 | GSK3A (0.42) | GSK3AGSK3B | |
| SCHEMBL19944177 | 0.88 | GSK3A (0.42) | GSK3AGSK3B | |
| SCHEMBL19944661 | 0.88 | GSK3A (0.42) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647693-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) | 2020-05-12 | — | — | US | disclosed |
| US-20190194159-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-27 | — | — | US | disclosed |
| WO-2018041091-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647693-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | EIF2AK2, POLRMT, SNRPE | GSK3A 360/4885GSK3B 314/4885ADORA1 1815/4885 |
| US-20190194159-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | EIF2AK2, POLRMT, SNRPE | GSK3A 360/4885GSK3B 314/4885ADORA1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.